Mind Medicine (MindMed) (MNMD) Scheduled to Post Earnings on Thursday

Mind Medicine (MindMed) (NASDAQ:MNMDGet Free Report) will post its quarterly earnings results after the market closes on Thursday, November 7th. Analysts expect Mind Medicine (MindMed) to post earnings of ($0.29) per share for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

Mind Medicine (MindMed) (NASDAQ:MNMDGet Free Report) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.18). On average, analysts expect Mind Medicine (MindMed) to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Mind Medicine (MindMed) Stock Down 1.7 %

Shares of MNMD opened at $6.34 on Thursday. The company has a 50-day simple moving average of $5.99 and a 200-day simple moving average of $7.35. The firm has a market capitalization of $457.40 million, a P/E ratio of -2.60 and a beta of 2.52. The company has a debt-to-equity ratio of 0.12, a quick ratio of 5.92 and a current ratio of 5.92. Mind Medicine has a 52 week low of $2.41 and a 52 week high of $12.22.

Insider Transactions at Mind Medicine (MindMed)

In other news, CEO Robert Barrow sold 19,771 shares of the stock in a transaction that occurred on Wednesday, September 25th. The shares were sold at an average price of $5.98, for a total transaction of $118,230.58. Following the sale, the chief executive officer now directly owns 545,772 shares of the company’s stock, valued at $3,263,716.56. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, insider Dan Karlin sold 6,871 shares of the stock in a transaction that occurred on Wednesday, September 25th. The shares were sold at an average price of $5.98, for a total transaction of $41,088.58. Following the sale, the insider now directly owns 344,656 shares of the company’s stock, valued at $2,061,042.88. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Robert Barrow sold 19,771 shares of the stock in a transaction that occurred on Wednesday, September 25th. The shares were sold at an average price of $5.98, for a total transaction of $118,230.58. Following the sale, the chief executive officer now directly owns 545,772 shares in the company, valued at $3,263,716.56. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 28,994 shares of company stock valued at $173,384. Corporate insiders own 2.26% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently issued reports on MNMD. Canaccord Genuity Group dropped their price target on shares of Mind Medicine (MindMed) from $16.00 to $14.00 and set a “buy” rating for the company in a research report on Monday, September 16th. Leerink Partners began coverage on shares of Mind Medicine (MindMed) in a research report on Monday, October 14th. They issued an “outperform” rating and a $20.00 price target for the company. HC Wainwright increased their price target on shares of Mind Medicine (MindMed) from $35.00 to $55.00 and gave the stock a “buy” rating in a research report on Thursday, August 29th. Leerink Partnrs raised shares of Mind Medicine (MindMed) to a “strong-buy” rating in a research report on Friday, October 11th. Finally, Roth Mkm began coverage on shares of Mind Medicine (MindMed) in a research report on Wednesday, July 24th. They issued a “buy” rating and a $36.00 price target for the company. Nine analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $25.38.

Read Our Latest Stock Analysis on MNMD

Mind Medicine (MindMed) Company Profile

(Get Free Report)

Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.

Featured Stories

Earnings History for Mind Medicine (MindMed) (NASDAQ:MNMD)

Receive News & Ratings for Mind Medicine (MindMed) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mind Medicine (MindMed) and related companies with MarketBeat.com's FREE daily email newsletter.